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Therapeutic angiogenesis is an emerging paradigm for the
management of ischemic pathologies. Proangiogenic Therapy is
limited, however, by the current inability to deliver angiogenic
factors in a sustained manner at the site of pathology. In this study,
we investigated a unique nonglycosylated active fragment of
hepatocyte growth factor/scatter factor, 1K1, which acts as a
potent angiogenic agent in vitro and in a zebrafish embryo and
a murine matrigel implant model. Furthermore, we demonstrate
that nanoformulating 1K1 for sustained release temporally alters
downstream signaling through the mitogen activated protein
kinase pathway, and amplifies the angiogenic outcome. Merging
protein engineering and nanotechnology offers exciting possibili-
ties for the treatment of ischemic disease, and furthermore allows
the selective targeting of downstream signaling pathways, which
translates into discrete phenotypes.
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Neovascularization in the adult holds the potential for ameli-orating ischemic disease, which is the leading cause of mor-
bidity and mortality in the United States (1). Ferrara and Kerbel
recently articulated that “therapeutic angiogenesis” is an emerging
and exciting frontier of cardiovascular medicine (2). However,
while early preclinical studies and phase I clinical trials exhibited
promising results with recombinant proteins or gene therapy,
more rigorous phase II and III studies have reported conflicting
outcomes (3–6). A recent review of these clinical trials highlighted
vector “washout” leading to inadequate duration of exposure to
the angiogenic agent as a key factor that may have impaired the
effectiveness of therapy (7). Indeed, it is now established that
sustained activation of downstream signal pathways promotes
cellular processes critical for angiogenesis (8). We rationalized
that harnessing a nanotechnology-based approach can enable a
temporal control over the presentation of the angiogenic factors
to the cellular target, thereby altering the activationof downstream
signal transduction.
While nanoformulation of angiogenic proteins is an attractive
strategy, the synthesis and instability of these large complex
glycosylated structures pose a significant barrier (9). Hepatocyte
growth factor/scatter factor (HGF/SF) is a potent angiogenic
agent (10), signaling through the Met receptor and downstream
MAPK and the PI3K pathways (11–12). Interestingly, the Met
receptor is upregulated during hypoxia, suggesting that the
ischemic tissue will be primed for activation by HGF/SF (13).
These results indicate that HGF/SF could emerge as an attractive
therapy for angiogenesis. However, HGF/SF is a heparin-binding
protein with a complex multidomain structure consisting of an
N-terminal (N) domain, four copies of the kringle domain (K1
to K4) and a C-terminal domain homologous to that of serine
proteineases (SP) (Fig. 1A) (14). Biologically active HGF/SF is
produced by proteolytic cleavage of the linker connecting the
fourth kringle and the SP domain yielding a two-chain (α/β)-
heterodimer, in which both the α- and the β-chain display consid-
erable heterogeneity due to five putative glycosylation sites: three
in the α-chain (residues 289, 397, and 471) and two in the β-chain
(residues 561 and 648).
In the present study, we combined protein engineering and
nanotechnology in order to maximize the therapeutic potential
of HGF/SF. The protein engineering experiments targeted
NK1, an alternatively spliced variant of the HGF/SF transcript
to yield the protein 1K1, a stable and nonglycosylated agonist
of the Met receptor, which exerted strong angiogenic activity.
Furthermore we encapsulated 1K1 in nanoparticles engineered
from biodegradable D, L-lactic acid-co-glycolic acid copolymer
to enable sustained release, and demonstrate that the temporal
release enables unique downstream signaling through the MAPK
pathway resulting in an enhanced angiogenic outcome in vitro
and in vivo. Our study opens up the possibility of combining
unique approaches to protein engineering and nanovectors for
modulating vascularization in impaired ischemic condition.
Results and Discussion
Engineering 1K1, a Nonglycosylated HGF/SF Variant. In the presence
of heparan sulfate or heparin, NK1 behaves as a partial receptor
agonist (14). In order to develop 1K1, a rational protein engineer-
ing approach was employed based on structural and functional
studies of NK1 (15), NK1-heparin complexes (16), and individual
N and K1 domains (17). NK1 binds heparin through two distinct
sites: a high-affinity site located in the N domain and formed by
the side chains of R73, K60, T61, R76, K62, and K58 and main
chain atoms of T61, K63, and G79 (18) and a low-affinity site in
the K1 domain comprising the side chains of K132, R134, K170,
and R181. The mutant 1K1 carries two reverse charge mutations
at K132 and R134 (1K1: K132E:R134E) that disrupt heparin
binding to the kringle domain (Fig. 1) and displays increased
signaling activity on several cell types compared to wild type
(16). The higher biological activity of 1K1 over NK1 is due to
two reasons: Firstly, as a result of the loss of the heparin-binding
site in K1, heparin interacts solely with the primary binding site in
the N domain and causes adjacent 1K1 dimers to bind Hepatocyte
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growth factor receptor (MNNG (N-Methyl-N'-nitro-Nnitroso-
guanidine) HOS Tranforming gene) (MET) on the same plane
(Fig. 1C) unlike NK1, where the heparin-binding sites of the K1
domain cause heparin to align adjacent NK1 dimers on a different
plane (Fig. 1B). Hence, 1K1 can form oligomeric ligand-receptor
complexes more readily than NK1. (A full description of the crystal
structure of the 1k1-heparin complex will be reported elsewhere.)
Secondly, preformed1K1-heparin complexes have greater binding
affinity for MET than NK1- heparin complexes as a result of
the different way in which the two proteins bind heparin as shown
by surface plasmon resonance (Fig. 1 E–F) and velocity and sedi-
mentation experiments (Fig. 1 G–H).
1K1 Induces Angiogenesis in Vitro by Binding to MET Kinase. The an-
giogenic phenotype is the culmination of discrete cellular steps
characterized by endothelial cell chemoinvasion, proliferation,
and tubulogenesis (18). As shown in Fig. S1, both HGF/SF
and 1K1 induced endothelial cell proliferation. Furthermore,
1K1-induced endothelial cell proliferation was inhibited by the
MET kinase inhibitor, PHA 665752, in a concentration-depen-
dent manner (Fig. S1C), which confirmed that 1K1 induces
angiogenesis through the Met receptor. Previous studies have re-
vealed that MET binding by HGF/SF ligand results in down-
stream signaling through the PI3K and the MAPK (10). To test
whether these pathways are activated in 1K1-mediated endothe-
lial cell proliferation, we pretreated the cells with LY294002 or
PD98059, which inhibit PI3K and MAPK respectively. As shown
in Fig. S1, both LY294002 and PD98059 inhibited 1K1-induced
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Fig. 1. Structural features of the 1K1-heparin complex and interaction with
the MET receptor (A) Domain structure of full length multidomain HGF/SF.
The α-chain consists of N-terminal domain (amino acids 32–121) and four
kringle domains(K1, K2, K3, and K4) and the β-chain contains serine proti-
nease domain (spdh domain). (B) Crystal structure of NK1-heparin complex
(16) (PDB accession 1GMO). Two NK1 dimers are shown bridged by heparin.
N and K domains are shown in blue and yellow, heparin is shown in red
(C) Crystal structure of 1K1-heparin complex (PDB accession 3MPK). Two
1K1 dimers are shown bridged by heparin. N and K domains are shown in
blue and gray, heparin is shown in red. The figures in B and C have been
drawnwith Pymol. Reverse mutations K132E and R134E were introduced into
K1 domain of 1K1 to inactivate the low-affinity heparin-binding sites. (D) and
(E). (D) Amino acid sequence of 1K1 demonstrating the mutated sites. Bind-
ing of NK1 (E) and 1K1 (F) to MET567 in the presence of 12mer heparin using
surface plasmon resonance. Twofold dilutions of each protein were used
from a concentration of top concentration of 200 nM. The concentration
of 12mer heparin in the sample and in the reaction buffer was 10 μM.
(G) and (H). Velocity sedimentation analysis of ternary complexes of NK1-
heparin-MET567 (G) and 1K1-heparin-MET567 (H). Data show plots of c(s)
against s*20,w. In the presence of 10mer heparin, the amount of ternary
complex is significantly higher for 1K1 than for NK1.
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Fig. 2. (A) Effect of pharmacological inhibitors on the 1K1-induced on
HUVECs tube formation on growth-factor-reduced matrigel. Graphs
(B) and (C) show the quantification of the images using three morphometric
analyses of average length of tubes and average number of nodes respec-
tively. The data represent mean SEM pixels from n ¼ 3. ** P < 0.01 vs. ve-
hicle-treated control; # P < 0.05 vs. 1K1(10−7 M]). (D) Representative Western
blot showing phospho Erk and total Erk and also phospho Akt and total Akt
expression in HUVECs treated with Met inhibitor PHA 665752 (10−6 M),
LY294002 (50 μM) and PD98059 (50 μM) for 2 h, followed by 1K1 for 10 mins.
The numbers indicate 1: vehicle, 2: HGF/SF (10−8 M), 3: 1K1 (10−7 M), 4: 1K1þ
PHA 665752 (10−6 M) 5: 1K1þ LY294002 (50 μM), 6: 1K1þ PD98059 (50 μM).
For sample no. 4, 5, and 6, 1K1 (10−7 M) were used along with the inhibitors.
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cell proliferation in a concentration-dependent manner, suggest-
ing that both the PI3K and MAPK pathways are implicated dur-
ing 1K1-induced endothelial cell proliferation.
We next tested whether 1K1 can induce endothelial tubulogen-
esis. As shown in Fig. 2, both HGF/SF and 1K1 induced signifi-
cant tubulogenesis compared with vehicle treatment when the
endothelial cells were plated on a three-dimensional Matrigel
matrix. Interestingly, 1K1-induced tubes were phenotypically
longer and had more nodes as compared with HGF/SF. Consis-
tent with the cell proliferation results, pretreatment of the human
umbilical vein endothelial cells (HUVECs) with 10−6 M
PHA665752 completely blocked 1K1-induced tubulogenesis
(Fig. 2 A–C). Additionally, both PD98059 and LY294002 inhib-
ited 1K1-induced tubulogenesis implicating these signaling path-
ways in the process (Fig. 2 A–C). Indeed, as seen in the Western
blots (Fig. 2D), incubation of endothelial cells with 1K1 resulted
in rapid phosphorylation of both ERK)and Akt, downstream
effectors of the MAPK and PI3K signaling pathways, which were
blocked by LY294002 and PD98059 respectively. Western blot
also revealed that pretreating the cells with 10−6 M PHA665752
blocked the 1K1-induced phosphorylation of ERK and Akt.
These results confirmed that 1K1 induces angiogenesis in vitro
by signaling through the sameMet-dependent pathways activated
by HGF/SF (10).
Synthesis and Characterization of 1K1-Nanoparticle.A key challenge
for therapeutic angiogenesis is the local and sustained delivery of
the angiogenic factors at the desired site of action (6). In an
elegant study, Richardson et al. demonstrated that sustained re-
lease of VEGF-165 and PDGF-BB, each with distinct kinetics,
from a single, structural polymer scaffold resulted in the rapid
formation of a mature vascular network (19). Furthermore, the
controlled intramyocardial delivery of platelet-derived growth
factor was found to improve postinfarction ventricular function
with increased vascularization (20). Similarly, in a recent study,
the intramuscular injection of pivastatin-loaded nanoparticles that
enabled sustained release of the drug resulted in enhanced angio-
genesis (21). To enable a sustained release formulation of 1K1,
we engineered nanoparticles from poly-lactic acid-glycolic acid
(PLGA) copolymer, which is biocompatible and biodegradable
and is approved by the FDA. 1K1 nanoparticles were made using
double emulsion/solvent extraction technique (22). Transmission
electron microscopy data confirmed the spherical shape and also
the diameter of the nanoparticles to be 60–140 nm (Fig. 3A), which
was validated by dynamic light scattering measurement (Fig. 3B).
The total loading efficiency of 1K1 in the nanoparticles, was de-
termined to be 54.27 7.12%. Sustained release of therapeutic
protein in biologically active form and subsequent degradation
are critical for biologic activity, and depend on desorption of
surface-bound molecules, diffusion through the nanoparticle
matrix and erosion of the latter. Kinetics of 1K1 release from
the nanoparticles over a 7 day period was determined by enzyme-
linked immunoabsorbent assay. As shown in Fig. 3C, there was an
initial phase of characteristic burst release associated with nano-
particles (22, 23) followed by a steady state release over a 7 day
period. This observation is consistent with previous reports where
VEGF entrapped in PLGAmicrosphere exhibited similar release
kinetics over a 30 day period (22).
1K1-NP Induces Angiogenesis in Vitro. The angiogenic activity of
1K1-nanoparticles (1K1-NP) was examined using HUVECs
proliferation as the biological read-out. As shown in Fig. 3 D–F,
treatment with 1K1-NP resulted in significant endothelial cell
proliferation as compared with vehicle, indicating that the process
of engineering the nanoparticles does not alter the biological
activity of 1K1. Furthermore, 1K1-NP-induced cell proliferation
was inhibited inpresenceofMETinhibitor, PHA665752 (Fig. 3D),
the PI3K inhibitor, LY294002, (Fig. 3E), and theMAPK inhibitor,
PD98059 (Fig. 3F), indicating that, following entrapment in the
nanoparticle, signaling ismediated by the samepathways activated
by soluble 1K1.
Interestingly, 1K1-NP was found to induce significantly greater
tubulogenesis as compared with empty vector or free 1K1, indi-
cating the sustained release of the angiogenic factor markedly
affected the angiogenic response (Fig. 4). To mechanistically
correlate the phenotypic distinctions with the temporal release,
we used Western blotting to evaluate the effect of 1K1-NP on
downstream signaling pathways. As shown in Fig. 4C, incubation
of endothelial cells with both 1K1-NP and 1K1 resulted in rapid
phosphorylation within 10 min. Pretreating the cells with
PHA665752 blocked the phosphorylation of ERK and Akt in-
duced by 1K1-NP. Pretreating the cells with 50 μM LY294002
abolished the phosphorylation of Akt while PD98059 reduced
the phosphorylation of ERK consistent with 1K1 activity pre-
viously observed. However, in the case of 1K1-NP, a sustained
activity was noted as shown by the increased phosphorylation
of ERK at 8.5 h posttreatment unlike treatment with 1K1
(Fig. 4D). Indeed, it is now well established that sustained activa-
Fig. 3. (A) Transmission electron microscopy (TEM)
image of 1K1-encapsulated nanoparticles (1K1-NP)
(Bar ¼ 500 nm). (B) Size distribution (in nm) of the
1K1-encapsulated nanoparticles by dynamic light
scattering experiment. (C) Graph shows release ki-
netics of 1K1 from the nanoparticle when incubated
in PBS at room temperature. The values on the Y-axis
represent the amount of 1K1 released from the 1K1-
NP in ug unit. (D) Effect ofMet inhibitor, PHA 665752,
on 1K1-NP induced HUVECs proliferation at 48 h.
(E) Effect of PI3 kinase inhibitor, LY294002, on 1K1-
NP induced HUVECs proliferation at 48 h. (F) Effect
of MAP kinase inhibitor, PD98059, on 1K1-NP
induced HUVECs proliferation at 48 h. The data
represent mean SEM from n ¼ 3. *** P < 0.001
vs. vehicle-treated control; ** P < 0.01 vs. vehicle-
treated control; ### P < 0.001 vs. 1K1(10−7 M); ##
P < 0.01 vs. 1K1(10−7 M); # P < 0.05 vs. 1K1(10−7 M).
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tion of MAPK signaling pathway is critical for tubulogenesis,
whereas transient activation is insufficient to induce suchmorpho-
logical alterations (8, 24, 25). Phenotypic quantification of the
vascular tubes also confirmed that pretreatment of the HUVECs
with PHA665752 (10−7 M), PD98059 (50 μM) or LY294002
(50 μM) blocked 1K1-NP-induced tubulogenesis (Fig. 4 A–B).
Zebrafish Angiogenesis Assay. The zebrafish (Danio rerio) is fast
emerging as an excellent model for studying neovascularization
(26, 27). To validate the angiogenic activity of 1K1 and 1K1-NP
in vivo, 1K1 or 1K1-NP were mixed with growth-factor-
reduced matrigel (Mgel) and injected into the yolk sac, next to
the subintestinal vessel.As shown inFig. 5, 1K1 induced significant
angiogenesis compared with empty vector as quantified by nodes
formed during sprouting of the subintestinal vessels. Interestingly,
at the 48 h time points, 1K1-NP exerted greater angiogenesis
than 1K1, which validates the hypothesis that sustained release
of angiogenic factors can result in enhanced angiogenesis.
Murine Matrigel Implant Assay. To further validate the angiogenic
efficacy of 1K1 in vivo, 1K1 or 1K1-NP mixed with growth-factor-
reduced matrigel was injected subcutaneously in mice at a dose of
200 nanogram (ng) of 1K1/scaffold. The scaffolds were main-
tained for 12 d, following which the animals were killed and
the skin everted to visualize the angiogenic response. Treatment
with 1K1 resulted in a strong angiogenic response as shown in
Fig. 6. Interestingly, 1K1-NP induced a significantly greater an-
giogenic response as compared with 1K1. To further validate the
gross morphology, the implants were cross-sectioned, immunola-
beled for von Willebrand factor, a marker for endothelial cells.
As shown in Fig. 6 (lower), 1K1-NP treatment (Fig. 6H) resulted
in a superior angiogenic outcome to free 1K1, consistent with the
observation in the zebrafish. These results confirm that sustained
release of growth factors could exert superior angiogenic
outcome.
Conclusions
While significant progress has been made towards inhibition of
angiogenesis in a pathological context such as in cancer, thera-
peutic angiogenesis in diseases characterized by insufficient
vascularization, such as in coronary ischemia, peripheral arterial
diseases, or in diabetic sores (4, 28–30), is still at a nascent stage.
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Fig. 4. (A) Effect of pharmacological inhibitors on
the 1K1-NP induced on HUVECs tube formation on
matrigel. (B) Graphs show the quantification of the
images using average length of tubes. The data
represent mean SEM pixels from n ¼ 3. * P < 0.05
vs. vehicle-treated control; ## P < 0.01 vs. 1K1
(10−7 M); # P < 0.05 vs. 1K1(10−7 M). (C) Representa-
tive Western blot showing phospho Erk and total Erk
and also phospho Akt and total Akt in HUVECs trea-
ted with Met inhibitor PHA 665752 (10−6 M),
LY294002 (50 μM) and PD98059 (50 μM) for 2 h,
followed by 10 min 1K1-NP and 1K1. The numbers
indicate 1: vehicle (PBS), 2: vehicle (empty PLGA),
3: freshly prepared 1K1 (0.5 × 10−7 M), 4: 1K1 incu-
bated at 37 °C for 24 h (0.5 × 10−7 M), 5: 1K1-NP
incubated at 37 °C for 24 h (0.5 × 10−7 M), 6: 1K1-NPþ
PHA665752 (10−6 M)7:1K1-NPþ LY294002 (50 μM),8:
1K1-NPþ PD98059 (50 μM). For sample no. 6, 7, and 8,
(0.5 × 10−7 M) 1K1-NP were used along with the
inhibitors. (D) Representative Western blot showing
phospho Erk and total Erk in HUVECs treated with
(0.5 × 10−7 M) 1K1 and (0.5 × 10−7 M) 1K1-NP for
8.5 h.
F
2
0
4
6
r
eb
m
u
n
eg
a r
evA
s
ed
o
nf
o
M
ge
l
PL
GA
 C
on
M
ge
l C
on
.
M
ge
l 1
K1
M
ge
l
1K
1-
NP
1K
1-
NPED
CBA
Fig. 5. Effect of 1K1 and 1K1-NP mediated angiogenesis in vivo using zebrafish model. 1K1 or 1K1-NP were injected with growth-factor-reduced matrigel
(Mgel) near the subintestinal vessel. SIVs were then stained with alkaline phosphate and visualized in bright field. (A): vehicle (Mgel); (B) empty PLGA in Mgel
(C) 1K1 inMgel, (D) 1K1-NP inMgel and (E) 1K1-NP. (F) Graph showsmorphometric quantification of the effect of treatment on angiogenesis. Data shownmean
SEM from n ¼ 3.
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We and others have previously demonstrated that HGF/SF can
mount a strong angiogenic response (12), both independently
of other growth factors (10) and by inducing expression of VEGF
(31). Furthermore, a study to assess the safety of intramuscular
injection of HGF/SF plasmid to improve limb perfusion in
patients with critical limb ischemia (the HGF-STAT trial) has
recently revealed that intramuscular injection of HGF plasmid
was safe and well tolerated, and limb tissue perfusion as mea-
sured by transcutaneous oxygen tension in patients with critical
limb ischemia was found to have significantly improved at the
highest doses used (32). These observations establish a strong
clinical rationale to use HGF/SF in the management of ischemic
diseases. However, the emerging hypothesis suggests that sus-
tained release of angiogenic agents could be critical in defining
the clinical outcome for therapeutic angiogenesis. In the present
study, we demonstrate that a rationally engineered variant of
HGF/SF can be integrated into a nanovector that alters the
temporal presentation of the growth factor to the target cells,
and thereby enhances the angiogenic outcome by modifying
the downstream signaling cascade.
A key hurdle in translating growth factors to the clinics fre-
quently lies in the heterogeneity of the polypeptide growth factor
due to extensive protein glycosylation, which poses regulatory
challenges for manufacturing. In the case of HGF/SF, additional
challenges are the complex multidomain structure of the native
protein that results in low production yields and a propensity of
the protein to aggregate in physiological buffers. In this study, we
investigated a truncated mutant of HGF/SF which can be ex-
pressed in high yields by yeast cells (unlike native HGF/SF), lacks
glycosylation sequences and retains strong signaling activity.
Next, we further improved the biological activity and therapeutic
potential of 1K1 by incorporating the protein in nanoparticles
from PLGA copolymer. While free 1K1 and 1K1-NP induced
similar levels of ERK phosphorylation at early time points, we
observed that the nanoparticle resulted in sustained activation
of the MAPK signaling in contrast to free 1K1. In a previous
study, the sustained activation of MAPK was reported to be cri-
tical for tubulogenesis while a transient activation was shown to
be sufficient for the induction of cell proliferation (8, 24–25). This
observation can possibly explain that while 1K1 and 1K1-NP
exhibited similar levels of cell proliferation, the latter resulted
in enhanced neovascularization in the in vivo matrigel implant
and zebrafish angiogenesis assay. Excitingly, this observation also
highlights the potential use of nanotechnology to temporally alter
signaling pathways through controlled release thereby enable the
dissection of distinct regulatory controls underlying biological
phenomena. These results address the emerging paradigm that
the sustained focal concentration of the active agent is critical
for therapeutic angiogenesis, and may offer a robust strategy
for the management of ischemic diseases.
Materials and Methods
Expression of 1K1 and HGF/SF. HGF/SF was produced from a derivative of the
mouse myeloma cell line NS0 transfected with a full length HGF/SF cDNA. 1K1
was produced from a derivative of the yeast Pichia pastoris transfected
with the 1K1 cDNA. Both proteins were purified from culture supernatants
using Heparin-Sepharose chromatography followed by cation exchange
chromatography on Mono S, yielding proteins >90% pure as judged by
SDS gel electrophoresis.
Surface Plasmon Resonance Experiments. A fragment of the Met ectodomain
corresponding to amino acids 25-567 (MET567) was used for immobilization
on single flow cells of a CM5 chip equilibrated with 20 mM phosphate
(pH 7.4), 150 mM NaCl, 50 μM EDTA, 0.005% Surfactant P20. The chip surface
was first activated using the CM5 amine coupling immobilization method in
the BIACore Control software (100 μL of 0.2 M 1-Ethyl-3-(3-dimethylamino-
propyl)carbodiimide mixed with 100 μL 0.05 M N-hydroxysuccinimide to give
reactive succinimide ester groups). Met567H was diluted in 10 mM sodium
acetate at a final concentration of 400 nM and injected, until a ΔRU of
∼1;500 was reached. Remaining active groups were blocked by injection
of 70 μL of 1 M ethanolamine (pH 8.5). As a negative control, another flow
cell of the CM5 chip was treated with the same program, but without
protein. The chip was then reequilibrated with 10 mM Hepes, 150 mM NaCl,
3 mM EDTA, 0.005% Tween-20 (HBS-EP) ð10 mM HepesðpH 7.4Þ;
150 mM NaCl;50 μM EDTA;0.005%Surfactant P20Þ þ 0.2 mg∕ml BSA and
then a range of protein concentrations (diluted in HBS-EPþ BSA) were
injected at 20 μL∕min for 60 min followed by a 300 s dissociation time.
The chip was regenerated using HBS-EP with 1 M NaCl.
Analytical Ultracentrifugation. Wild-type NK1, 1K1, and MET567 proteins
were dialyzed against 25 mM phosphate, 150 mM NaCl, pH 7.4 prior to
centrifugation. Measurements weremade using a Beckman Optima XLA ana-
lytical ultracentrifuge using an intermediate speed sedimentation velocity
method. Data were acquired in continuous mode analyzed using the
program Sedfit in which the least-squares g(s*) sedimentation coefficient
distribution is computed, where c is the concentration (in absorbance units),
r is radius (in cm), t is time (in seconds), c0 is the loading concentration (in
absorbance units), w is the angular velocity of the rotor (in radians∕second)
and rm is the radius at the meniscus (in cm). Data were collected with incident
light set at 278 nm. The g(s*) profiles were fitted with normal (Gaussian)
distributions using ProFit, a nonlinear least-squares fitting package (Quan-
tum Soft).
Engineering 1K1 Nanoparticle. 1K1 nanoparticles were made using the double
emulsion/solvent extraction technique. Emulsion 1 was prepared using 50 mg
PLGA (50∶50) (MW 40–75 KDa) dissolved in 10 mL of acetonitrile. 104 ug 1K1
was encapsulated in 50 mg PLGA by sonication. Emulsion 2 was prepared
using 0.5 g PVA (polyvinyl alcohol, Sigma, MW 9,000–10,000) and was
dissolved in 9.3 mL of double distilled water and 0.7 mL of acetonitrile.
An organic extraction buffer was made by dissolving 0.2 g PVA in 186 mL
of double distilled water and 14 mL of acetonitrile. 1 mL of emulsion 2
was added to emulsion 1 and the solution was vortexed for ∼1 min and
was added to that organic buffer. This solution was stirred for 12 h to eva-
porate acetonitrile. This solution was centrifuged at 193,190 x 4 g (Sorvall
Ultra Pro 80) for 1 h to pellet the nanoparticles, which was washed again
with water and then characterized for size and morphology using a Nano-
Fig. 6. Effect of 1K1 (200 ng∕plug) and 1K1-NP
(200 ng∕plug) induced angiogenesis in growth-fac-
tor-reduced matrigel implants in vivo. Upper (A–D)
shows gross morphology of the implants after evert-
ing the murine skin, and Bottom (E–H) shows cross
sections where blood vessels are delineated with
von Willebrand factor immunolabeling and appear
red. Nuclei were counterstained with DAPI and ap-
pear blue. Images were captured at 512 × 512 pixels
resolution. A and E: vehicle, B and F: empty NP,
C and G: 1K1, D and H: 1K1 NP.
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zetasizer (Malvern) and transmission electron microscopy (TEM). The samples
was spotted on copper grids and stained with uranyl acetate for TEM.
Cell Proliferation Assay. HUVECs were grown in 96 well plate and synchro-
nized in 0.1% FBS prior to treatment with growth factors for 24, 48, or
72 h. Cells were treated with signal transduction inhibitors for 2 h prior to
addition of growth factors. The percentage of viable cells was quantified
with 3-(4, 5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium (MTS) from the Cell Titer 96 Aqueous One Solution
kit measured at 490 nm using a Versamax plate reader. Final absorbance, cor-
responding to cell proliferation, was plotted after subtracting background
values from each data point.
HUVEC Tube Assay. HUVECs (25,000 cells per well) were seeded in a 96-well
plate coated with growth-factor-reduced matrigel. Cells were treated with
inhibitors for 2 h before adding the growth factors. After 8 h, images were
taken under inverted light microscopy at 10× magnification (Nikon Eclipse).
Immunoblotting. HUVECs (70% confluent) were treated with 1K1, 1K1-NP,
and HGF/SF (positive control) for 10 min and directly lysed in 3× loading
buffer. The cells were pretreated with signal transduction inhibitors for at
least 2 h before growth-factor treatment. Proteins were resolved on 10%
SDS-PAGE gel. Membranes were probed for phosphorylated and total forms
of MET, Akt, and Erk. Proteins were detected with horseradish peroxidase-
conjugated anti-rabbit secondary antibodies and Lumi-LightPLUS Western
Blotting Substrate (Roche Applied Science). The blots were developed
using GeneSnap and optical density was quantified using Gene Tools (both
from SynGene). Predetermined molecular weights standards were used as
markers. Proteins were normalized against actin.
Zebrafish Angiogenesis Assay. Zebrafish (Tΰbingen AB) (2 d post fertilization),
were anesthetized in Tricaine (MESAB-ethyl-m-aminobenzoate methanesul-
phonate, 1% Na2HPO4, pH 7.0) and positioned on their side in a 1% agarose
injection mold, and 9.2 nL of each sample was injected into the yolk sac next
to the subintestinal vessel (SIV) using a Nanoject II injection device (Drum-
mond Scientific). Zebrafish injected with growth-factor-reduced matrigel
and 1 μM 1K1 as free or in nanoparticles were monitored for 24 and
48 h. Brightfield imaging was performed with a Nikon SMZ1500 stereomicro-
scope and a SPOT Flex camera.
in Vivo Matrigel Angiogenesis Assay in Mouse. Growth-factor-reduced
matrigel (BD), mixed with growth factors were injected subcutaneously into
balb/c mice. Mice were divided in two four groups: (A) vehicle control with
growth-factor-reduced matrigel, (B) vehicle control with empty PLGA and
growth-factor-reduced matrigel, (C) matrigel plug with 200 ng free 1K1
and (D) matrigel plug with 200 ng 1K1-NP. On day 12, gross response in
the form of blood vessels formed (angiogenesis) was recorded with a
high-resolution digital camera (Canon). The implants were excised and cryo-
frozen in optimal cutting temperature compound for immunohistochemistry.
Immunohistochemistry. The matrigel cryosections (18 μm) were fixed in −20 °C
with ice cold methanol and probed overnight with primary rabbit antibody
against vonWillebrand factor (Dako) at 4 °C in blocking buffer. Samples were
then probed with Alexa fluor 594 conjugated anti-rabbit secondary antibody
at room temperature for 2 h. Nuclei were counterstained with DAPI.
Images were captured with immunofluorescence microscope (Nikon Eclipse)
at 10× magnification.
Statistical Analysis. Statistical significance was tested by using 1-way ANOVA
followed by Dunnett’s or Friedman’s post hoc test. Bonferroni’s test was used
to test for overall dose-response effects (Graphical Prism 3 software). A value
of P < 0.05 was considered significant.
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